Charcot-Marie-Tooth disease type 2A (CMT2A), arising from mitofusin 2 (MFN2) gene mutations, is the most common inherited axonal neuropathy affecting motor and sensory neurons. The cellular and molecular mechanisms by which MFN2 mutations determine neuronal degeneration are largely unclear. No effective treatment exists for CMT2A, which has a high degree of genetic/phenotypic heterogeneity. The identification of mutations in MFN2 has allowed the generation of diverse transgenic animal models, but to date, their ability to recapitulate the CMT2A phenotype is limited, precluding elucidation of its pathogenesis and discovery of therapeutic strategies. This review will critically present recent progress in in vivo CMT2A disease modeling, discoveries, drawbacks and limitations, current challenges, and key reflections to advance the field towards developing effective therapies for these patients.
Animal Models of CMT2A: State-of-art and Therapeutic Implications / R. De Gioia, G. Citterio, E. Abati, M. Nizzardo, N. Bresolin, G.P. Comi, S. Corti, F. Rizzo. - In: MOLECULAR NEUROBIOLOGY. - ISSN 0893-7648. - 57:12(2020 Dec), pp. 5121-5129. [10.1007/s12035-020-02081-3]
Animal Models of CMT2A: State-of-art and Therapeutic Implications
E. Abati;M. Nizzardo;N. Bresolin;G.P. Comi;S. CortiPenultimo
;F. Rizzo
Ultimo
2020
Abstract
Charcot-Marie-Tooth disease type 2A (CMT2A), arising from mitofusin 2 (MFN2) gene mutations, is the most common inherited axonal neuropathy affecting motor and sensory neurons. The cellular and molecular mechanisms by which MFN2 mutations determine neuronal degeneration are largely unclear. No effective treatment exists for CMT2A, which has a high degree of genetic/phenotypic heterogeneity. The identification of mutations in MFN2 has allowed the generation of diverse transgenic animal models, but to date, their ability to recapitulate the CMT2A phenotype is limited, precluding elucidation of its pathogenesis and discovery of therapeutic strategies. This review will critically present recent progress in in vivo CMT2A disease modeling, discoveries, drawbacks and limitations, current challenges, and key reflections to advance the field towards developing effective therapies for these patients.File | Dimensione | Formato | |
---|---|---|---|
Gioia2020_Article_AnimalModelsOfCMT2AState-of-ar (1) AIR.pdf
accesso aperto
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
519.3 kB
Formato
Adobe PDF
|
519.3 kB | Adobe PDF | Visualizza/Apri |
Gioia2020_Article_AnimalModelsOfCMT2AState-of-ar.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
1.27 MB
Formato
Adobe PDF
|
1.27 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.